<DOC>
	<DOCNO>NCT01488851</DOCNO>
	<brief_summary>Prospective observational multi central cohort study assess incidence osteo necrosis jaw cancer patient bone metastasis start Zoledronic acid treatment</brief_summary>
	<brief_title>Study Assess Incidence ONJ Pts With Bone Mets Starting Zoledronic Acid Treatment</brief_title>
	<detailed_description>Prospective observational multi central cohort study assess incidence osteo necrosis jaw ( ONJ ) pts bone metastasis start Zoledronic acid treatment</detailed_description>
	<mesh_term>Zoledronic acid</mesh_term>
	<criteria>1 . Bone metastasis multiple myeloma , solid tumor , malignancy intravenous bisphosphonate clinical indication treatment metastatic bone disease . 2 . All participant must plan receive zoledronic acid ( sole bisphosphonate therapy ) within 30 day registration . Patients previously treat bisphosphonate therapy eligible follow criterion apply : 1 . Patients may previously receive 3 dos intravenous bisphosphonate therapy ibandronate , pamidronate zoledronic acid low bone mass ( osteopenia osteoporosis ) within 3 year prior registration 2 . Patients may receive intravenous bisphosphonate therapy ibandronate , pamidronate zoledronic acid treat metastatic bone disease within 90 day prior registration . Patients receive regimen metastatic bone disease prior 90 day registration eligible , c. Prior oral bisphosphonate therapy time prior registration allow . 3 . No preexist diagnosis ONJ . 4 . No history radiation maxillofacial area administer therapeutic intent treatment cancer . 5 . Zubrod performance status 03 . 6 . Willing physically able comply study procedures assessment . 7 . Can concurrently participate therapeutic nontherapeutic clinical trial . 8 . No prior malignancy allow except follow : adequately treat basal cell squamous cell skin cancer , situ cervical cancer , adequately treated Stage I II cancer patient currently complete remission , cancer patient diseasefree 5 year . 9 . Must inform investigational nature study must sign give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Osteo necrosis Jaw</keyword>
</DOC>